- Home
- OKYO vs MAIA Comparison
OKYO vs MAIA Comparison
Compare OKYO & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OKYO | MAIA |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.7M | 79.0M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | OKYO | MAIA |
|---|---|---|
| Price | $1.58 | $1.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.33 | N/A |
| AVG Volume (30 Days) | 56.9K | ★ 1.0M |
| Earning Date | 07-18-2025 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $0.87 |
| 52 Week High | $3.35 | $3.19 |
Technical Indicators
Market Signals| Indicator | OKYO | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 53.10 |
| Support Level | $1.47 | $1.22 |
| Resistance Level | $1.73 | $1.46 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 52.72 | 48.10 |
Price Performance
Historical ComparisonAbout OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.